trending Market Intelligence /marketintelligence/en/news-insights/trending/kuzzdebxx0rwzqxgcx0nw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Opko to review phase 3 study on HGH drug due to outliers

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Opko to review phase 3 study on HGH drug due to outliers

Opko Health Inc.'s phase 3 study of its investigational long-acting human growth hormone product, hGH-CTP, in adults with growth hormone deficiency did not achieve its primary endpoint.

The drug failed to show a statistical difference compared to placebo in changing the trunk fat mass from baseline to 26 weeks.

However, after unblinding the study, the company said it has identified one or more outliers that might have affected the primary outcome and plans to undertake a further review of the study population as soon as possible.

Opko has also initiated a phase 3 study in pre-pubertal growth hormone deficient children to evaluate weekly treatment with the drug versus daily injections of Genotropin.

The company has a worldwide collaboration and license agreement with Pfizer Inc. for the development and commercialization of hGH-CTP. Under the agreement, Opko is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product.